The British Society for Haematology has published updated guidelines for the diagnosis and management of chronic myeloid leukemia in adults and children.
CP-CML patients who remain on first-line TKI therapy have better clinical responses than patients who switch within the first 3 years.
Most patients with CML are being prescribed costly second-generation TKIs, even though generic imatinib has been available since 2016.
Lack of initial response to imatinib might indicate need to switch to dasatinib.
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.